NRTX-1001 is being assessed for drug-resistant mesial temporal lobe epilepsy
Category: News
CLM-HT01 improved blood pressure and minimised adverse reactions in patients
The aggressive type of cancer accounts for 13% of all lung cancer cases worldwide
The report includes five recommendations for the government to address these issues
The projects will focus on healthcare in LMICs in the event of extreme weather
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
The platform delivers digitalised patient data to improve clinical trials and development
The chip removes cells, which could become tumours, before they are implanted in a patient
OART is increasingly emerging to assess and adapt treatment for cancer patients